Axsome Therapeutics, Inc. (AXSM)

$69.71

+0.9

(+1.31%)

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Axsome Therapeutics, Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 46.7M → 71.53M (in $), with an average increase of 19.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -62.19M → -98.65M (in $), with an average decrease of 58.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 51.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 214.7%

Performance

  • $68.16
    $70.78
    $69.71
    downward going graph

    2.22%

    Downside

    Day's Volatility :3.7%

    Upside

    1.51%

    downward going graph
  • $55.02
    $98.40
    $69.71
    downward going graph

    21.07%

    Downside

    52 Weeks Volatility :44.09%

    Upside

    29.16%

    downward going graph

Returns

PeriodAxsome Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-17.5%
-0.7%
0.0%
6 Months
7.16%
6.6%
0.0%
1 Year
-4.31%
3.7%
-1.5%
3 Years
34.24%
14.0%
-21.8%

Highlights

Market Capitalization
3.3B
Book Value
$4.03
Earnings Per Share (EPS)
-5.27
PEG Ratio
0.0
Wall Street Target Price
123.0
Profit Margin
-88.41%
Operating Margin TTM
-77.68%
Return On Assets TTM
-24.86%
Return On Equity TTM
-159.21%
Revenue TTM
270.6M
Revenue Per Share TTM
5.96
Quarterly Revenue Growth YOY
193.5%
Gross Profit TTM
45.9M
EBITDA
-182.4M
Diluted Eps TTM
-5.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.8
EPS Estimate Next Year
0.98
EPS Estimate Current Quarter
-1.17
EPS Estimate Next Quarter
-1.1

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Axsome Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
14
Hold
3
3
3
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 76.45%

Current $69.71
Target $123.00

Technicals Summary

Sell

Neutral

Buy

Axsome Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
-3.9%
7.16%
-4.31%
34.24%
364.42%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
NA
NA
0.0
-3.8
-1.59
-0.25
NA
4.03
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
Buy
$3.3B
364.42%
NA
-88.41%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • RTW INVESTMENTS, LLC

    9.48%
  • Vanguard Group Inc

    7.80%
  • BlackRock Inc

    6.84%
  • Fairmount Funds Management LLC

    4.98%
  • Bvf Inc

    4.50%
  • Citadel Advisors Llc

    2.73%

Corporate Announcements

  • Axsome Therapeutics, Inc. Earnings

    Axsome Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.

Organization
Axsome Therapeutics, Inc.
Employees
545
CEO
Dr. Herriot Tabuteau M.D.
Industry
Health Technology

FAQs